OBJECTIVES: Coated-platelets are a subset of platelets produced by dual-agonist activation with collagen and thrombin. These platelets retain full-length amyloid precursor protein on their surface, are elevated in patients with amnestic as compared to nonamnestic mild cognitive impairment (MCI), and correlate with disease progression in Alzheimer disease (AD). Prompted by these findings, we investigated the association between coated-platelet production in amnestic MCI and rate of progression to AD. METHODS: Coated-platelet levels were assayed in 74 patients with amnestic MCI who were subsequently followed longitudinally for up to 36 months in an outpatient dementia clinic. Levels are reported as percent of cells converted into coated-platelets. Subjects were categorized into tertiles of coated-platelet levels. The distributions of time to progression to AD were estimated for each tertile using cumulative incidence curves and compared statistically using a log-rank test. Cox proportional hazards regression was used to adjust for potential confounders. RESULTS: The 24-month cumulative incidence of progression to AD was different among tertiles: 4% for the first tertile (lowest coated-platelet levels), 13% for the second tertile, and 37% for the third tertile (overall log-rank test, p = 0.02). The hazard rate of progression to AD for patients in the highest coated-platelet tertile was 5.1 times that for patients in the lowest tertile (p = 0.04), whereas the hazard rate for the middle tertile was similar to that for the lowest tertile (hazard rate ratio = 1.5, p = 0.7). CONCLUSIONS: Elevated coated-platelet levels in patients with amnestic MCI are associated with increased risk for progression to AD.
OBJECTIVES: Coated-platelets are a subset of platelets produced by dual-agonist activation with collagen and thrombin. These platelets retain full-length amyloid precursor protein on their surface, are elevated in patients with amnestic as compared to nonamnestic mild cognitive impairment (MCI), and correlate with disease progression in Alzheimer disease (AD). Prompted by these findings, we investigated the association between coated-platelet production in amnestic MCI and rate of progression to AD. METHODS: Coated-platelet levels were assayed in 74 patients with amnestic MCI who were subsequently followed longitudinally for up to 36 months in an outpatientdementia clinic. Levels are reported as percent of cells converted into coated-platelets. Subjects were categorized into tertiles of coated-platelet levels. The distributions of time to progression to AD were estimated for each tertile using cumulative incidence curves and compared statistically using a log-rank test. Cox proportional hazards regression was used to adjust for potential confounders. RESULTS: The 24-month cumulative incidence of progression to AD was different among tertiles: 4% for the first tertile (lowest coated-platelet levels), 13% for the second tertile, and 37% for the third tertile (overall log-rank test, p = 0.02). The hazard rate of progression to AD for patients in the highest coated-platelet tertile was 5.1 times that for patients in the lowest tertile (p = 0.04), whereas the hazard rate for the middle tertile was similar to that for the lowest tertile (hazard rate ratio = 1.5, p = 0.7). CONCLUSIONS: Elevated coated-platelet levels in patients with amnestic MCI are associated with increased risk for progression to AD.
Authors: D Neary; J S Snowden; L Gustafson; U Passant; D Stuss; S Black; M Freedman; A Kertesz; P H Robert; M Albert; K Boone; B L Miller; J Cummings; D F Benson Journal: Neurology Date: 1998-12 Impact factor: 9.910
Authors: B Winblad; K Palmer; M Kivipelto; V Jelic; L Fratiglioni; L-O Wahlund; A Nordberg; L Bäckman; M Albert; O Almkvist; H Arai; H Basun; K Blennow; M de Leon; C DeCarli; T Erkinjuntti; E Giacobini; C Graff; J Hardy; C Jack; A Jorm; K Ritchie; C van Duijn; P Visser; R C Petersen Journal: J Intern Med Date: 2004-09 Impact factor: 8.989
Authors: Ann B Ragin; Gypsyamber D'Souza; Sandra Reynolds; Eric Miller; Ned Sacktor; Ola A Selnes; Eileen Martin; Barbara R Visscher; James T Becker Journal: J Neurovirol Date: 2011-09-29 Impact factor: 2.643
Authors: Ole A Andreassen; Danielle Posthuma; Douglas P Wightman; Iris E Jansen; Jeanne E Savage; Alexey A Shadrin; Shahram Bahrami; Dominic Holland; Arvid Rongve; Sigrid Børte; Bendik S Winsvold; Ole Kristian Drange; Amy E Martinsen; Anne Heidi Skogholt; Cristen Willer; Geir Bråthen; Ingunn Bosnes; Jonas Bille Nielsen; Lars G Fritsche; Laurent F Thomas; Linda M Pedersen; Maiken E Gabrielsen; Marianne Bakke Johnsen; Tore Wergeland Meisingset; Wei Zhou; Petroula Proitsi; Angela Hodges; Richard Dobson; Latha Velayudhan; Karl Heilbron; Adam Auton; Julia M Sealock; Lea K Davis; Nancy L Pedersen; Chandra A Reynolds; Ida K Karlsson; Sigurdur Magnusson; Hreinn Stefansson; Steinunn Thordardottir; Palmi V Jonsson; Jon Snaedal; Anna Zettergren; Ingmar Skoog; Silke Kern; Margda Waern; Henrik Zetterberg; Kaj Blennow; Eystein Stordal; Kristian Hveem; John-Anker Zwart; Lavinia Athanasiu; Per Selnes; Ingvild Saltvedt; Sigrid B Sando; Ingun Ulstein; Srdjan Djurovic; Tormod Fladby; Dag Aarsland; Geir Selbæk; Stephan Ripke; Kari Stefansson Journal: Nat Genet Date: 2021-09-07 Impact factor: 41.307
Authors: Bappaditya Ray; Vijay M Pandav; Eleanor A Mathews; David M Thompson; Lance Ford; Lori K Yearout; Bradley N Bohnstedt; Shuchi Chaudhary; George L Dale; Calin I Prodan Journal: Transl Stroke Res Date: 2017-12-09 Impact factor: 6.829
Authors: Laura E Donovan; Eric B Dammer; Duc M Duong; John J Hanfelt; Allan I Levey; Nicholas T Seyfried; James J Lah Journal: Alzheimers Res Ther Date: 2013-06-13 Impact factor: 6.982